Gross Proceeds of Offering Total $167.1 Million
NEWARK, Calif.--(BUSINESS WIRE)--
Revance Therapeutics, Inc. (NASDAQ: RVNC), a biotechnology company
developing botulinum toxin products for use in treating aesthetic and
therapeutic conditions ("Revance" or the "Company"), today announced the
closing of an underwritten public offering of 6,139,515 shares of its
common stock at a price to the public of $31.00 per share. In the
offering, the Company issued and sold 5,389,515 shares, including the
exercise in full by the underwriters of their option to purchase 550,806
additional shares of common stock from the Company, and certain
stockholders of the Company (the "Selling Stockholders") sold 750,000
shares, including the exercise in full by the underwriters of their
option to purchase 250,000 additional shares of common stock from the
Selling Stockholders. The gross proceeds to the Company from the
offering, before deducting the underwriters' discounts and other
estimated offering expense payable by the Company, were approximately
$167.1 million. The Company did not receive any proceeds from the sale
of the shares by the Selling Stockholders.
Goldman Sachs & Co. LLC and Cowen acted as book-running managers,
Barclays acted as joint lead manager, and Cantor Fitzgerald & Co.,
William Blair & Company, L.L.C. and SunTrust Robinson Humphrey acted as
co-managers for the offering.
A shelf registration statement relating to the securities described
above was filed with the Securities and Exchange Commission on December
5, 2017 and automatically became effective the same day. The offering
was made only by means of a prospectus supplement. Copies of the final
prospectus supplement and accompanying prospectus relating to the public
offering may be obtained by contacting Goldman Sachs & Co. LLC,
Prospectus Department, 200 West Street, New York, NY 10282, telephone:
1-866-471-2526, facsimile: 212-902-9316 or by emailing Prospectusfirstname.lastname@example.org;
or Cowen and Company, LLC, c/o Broadridge Financial Services, Attention:
Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717,
Telephone: 631-274-2806, Fax: 631-254-7140.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there be any
sale of these securities in any state or other jurisdiction in which
such offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of any such
state or other jurisdiction.
About Revance Therapeutics, Inc.
Revance is a clinical-stage biotechnology company focused on the
development, manufacturing, and commercialization of novel botulinum
toxin products for multiple aesthetic and therapeutic indications.
Revance is leveraging its proprietary portfolio of botulinum toxin type
A compounds, formulated with its patented and proprietary peptide
technology, to address unmet needs in large and growing neurotoxin
"Revance Therapeutics" and the Revance logo are registered trademarks of
Revance Therapeutics, Inc.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171211005692/en/
Revance Therapeutics, Inc.:
Ami Bavishi, 212-213-0006
Mariann Caprino, 917-242-1087
Nadine Tosk, 504-453-8344
Source: Revance Therapeutics, Inc.
News Provided by Acquire Media